-
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
NCT04370587 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Massachusetts: Boston
-
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
NCT07070232 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Massachusetts: Boston
-
A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors
NCT07584226 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Massachusetts: Boston
-
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
NCT06150664 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Massachusetts: Boston
-
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
NCT06581406 ·
Phase: Phase 2, Phase 3 ·
Ages: No age limits stated ·
Sex: All (male and female)
· Massachusetts: Boston
-
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
NCT07492680 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Massachusetts: Boston
-
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
NCT05669430 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Massachusetts: Boston
-
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
NCT02332668 ·
Phase: Phase 1, Phase 2 ·
Ages: 6 Months to 17 Years ·
Sex: All (male and female)
· Massachusetts: Boston
-
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
NCT05592626 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Massachusetts: Boston
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
NCT05538130 ·
Phase: Phase 1 ·
Ages: 16 Years and older ·
Sex: All (male and female)
· Massachusetts: Boston, Waltham
-
A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
NCT05355701 ·
Phase: Phase 1 ·
Ages: 16 Years and older ·
Sex: All (male and female)
· Massachusetts: Boston, Newton
-
A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
NCT06624644 ·
Phase: Phase 2, Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Massachusetts: Boston
-
ACTengine® IMA203 Combined With mRNA-4203
NCT06946225 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Massachusetts: Boston
-
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
NCT03686124 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Massachusetts: Boston
-
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
NCT05136196 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Massachusetts: Boston, Springfield, Stoneham
-
Clonal Hematopoiesis Chemotherapy and Radiation Effects Study
NCT07675967 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Massachusetts: Boston
-
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
NCT05334069 ·
Phase: Not specified ·
Ages: 40 Years to 75 Years ·
Sex: All (male and female)
· Massachusetts: Jamaica Plain
-
Cryoablation+Ipilimumab+Nivolumab in Melanoma
NCT05779423 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Massachusetts: Boston
-
DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma
NCT07288112 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Massachusetts: Boston
-
High-Intensity Exercise and High-Fiber Diet for Immunotherapy Outcomes in Melanoma Patients: The DUO Trial
NCT06298734 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Massachusetts: Boston
-
IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
NCT06112314 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Massachusetts: Boston
-
Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the Liver
NCT07364474 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Massachusetts: Boston
-
InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer
NCT05463796 ·
Phase: Not specified ·
Ages: No age limits stated ·
Sex: All (male and female)
· Massachusetts: Boston
-
Integrated Cancer Repository for Cancer Research
NCT02012699 ·
Phase: Not specified ·
Ages: 19 Years to 110 Years ·
Sex: All (male and female)
· Massachusetts: Holyoke
-
Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma
NCT05428007 ·
Phase: Phase 2 ·
Ages: 18 Years to 100 Years ·
Sex: All (male and female)
· Massachusetts: Boston
-
Neoadjuvant Darovasertib in Primary Uveal Melanoma
NCT07015190 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Massachusetts: Boston
-
Neurocutaneous Melanocytosis Registry
NCT04548817 ·
Phase: Not specified ·
Ages: No age limits stated ·
Sex: All (male and female)
· Massachusetts: Boston
-
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
NCT05059444 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Massachusetts: Boston
-
Palbociclib and Pembrolizumab In Central Nervous System Metastases
NCT02896335 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Massachusetts: Boston
-
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
NCT04787042 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Massachusetts: Boston
-
Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors
NCT05280314 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Massachusetts: Boston
-
Project: Every Child for Younger Patients With Cancer
NCT02402244 ·
Phase: Not specified ·
Ages: Up to 25 Years ·
Sex: All (male and female)
· Massachusetts: Boston, Springfield, Worcester
-
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
NCT06743126 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Massachusetts: Boston
-
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
NCT03452774 ·
Phase: Not specified ·
Ages: No age limits stated ·
Sex: All (male and female)
· Massachusetts: Worcester
-
Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
NCT06425926 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Massachusetts: Boston
-
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
NCT04899908 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Massachusetts: Boston
-
Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma
NCT06585410 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Massachusetts: Beverly, Boston
-
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
NCT05379985 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Massachusetts: Boston
-
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
NCT04485013 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Massachusetts: Boston
-
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
NCT05549297 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Massachusetts: Boston
-
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
NCT04851119 ·
Phase: Phase 1, Phase 2 ·
Ages: 12 Months to 30 Years ·
Sex: All (male and female)
· Massachusetts: Boston
-
The Cancer of the Pancreas Screening-5 CAPS5)Study
NCT02000089 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Massachusetts: Boston
-
Video Education With Result Dependent dIsclosure
NCT05225428 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Massachusetts: Boston